Three clinical trials, two phase 3 and one phase 2, have been designed to compare the efficacy of anti-PD-L1 in combination with BRAF/MEK inhibitors in BRAFV600-mutant melanoma [30,32,33]. Here, MAP2K7 is linked to melanoma.